Full text is available at the source.
Abstract
Nearly 3 billion individuals worldwide were living with either obesity or overweight in 2022.
- Obesity is classified as a chronic and progressive disease, not just excess body weight.
- It is associated with increased risks of type 2 diabetes, cardiovascular disease, metabolic-associated fatty liver disease, and mental health disorders.
- Six medications are currently approved for long-term obesity management in the U.S., with glucagon-like peptide receptor agonists leading in effectiveness.
- New dual and triple combination therapies are being developed, potentially enhancing efficacy and metabolic outcomes.
- Long-acting and oral formulations are anticipated to improve patient adherence and accessibility to obesity treatment.
- India's recent obesity guideline promotes early pharmacotherapy initiation and a stage-based classification system.
Simplified